Comparison of high-dose rate prostate brachytherapy dose distributions with iridium-192, ytterbium-169, and thulium-170 sources.
Identifieur interne : 000447 ( PubMed/Curation ); précédent : 000446; suivant : 000448Comparison of high-dose rate prostate brachytherapy dose distributions with iridium-192, ytterbium-169, and thulium-170 sources.
Auteurs : Devan Krishnamurthy [États-Unis] ; Vivian Weinberg ; J Adam M. Cunha ; I-Chow Hsu ; Jean PouliotSource :
- Brachytherapy [ 1873-1449 ]
Descripteurs français
- KwdFr :
- Adénocarcinome (radiothérapie), Curiethérapie (), Dosimétrie en radiothérapie, Humains, Mâle, Planification de radiothérapie assistée par ordinateur (), Radio-isotopes, Radio-isotopes de l'iridium (usage thérapeutique), Radiométrie, Thulium (usage thérapeutique), Tumeurs de la prostate (radiothérapie), Ytterbium (usage thérapeutique).
- MESH :
- radiothérapie : Adénocarcinome, Tumeurs de la prostate.
- usage thérapeutique : Radio-isotopes de l'iridium, Thulium, Ytterbium.
- Curiethérapie, Dosimétrie en radiothérapie, Humains, Mâle, Planification de radiothérapie assistée par ordinateur, Radio-isotopes, Radiométrie.
English descriptors
- KwdEn :
- Adenocarcinoma (radiotherapy), Brachytherapy (methods), Humans, Iridium Radioisotopes (therapeutic use), Male, Prostatic Neoplasms (radiotherapy), Radioisotopes, Radiometry, Radiotherapy Dosage, Radiotherapy Planning, Computer-Assisted (methods), Thulium (therapeutic use), Ytterbium (therapeutic use).
- MESH :
- chemical , therapeutic use : Iridium Radioisotopes, Thulium, Ytterbium.
- methods : Brachytherapy, Radiotherapy Planning, Computer-Assisted.
- radiotherapy : Adenocarcinoma, Prostatic Neoplasms.
- Humans, Male, Radioisotopes, Radiometry, Radiotherapy Dosage.
Abstract
Recent studies have identified that among different available radionuclides, the dose characteristics and shielding properties of ytterbium-169 ((169)Yb) and thulium-170 ((170)Tm) may suit high-dose rate (HDR) brachytherapy needs. The purpose of this work was to compare clinically optimized dose distributions using proposed (169)Yb and (170)Tm HDR sources with the clinical dose distribution from a standard microSelectron V2 HDR iridium-192 ((192)Ir) brachytherapy source (Nucletron B.V., Veenendaal, The Netherlands).
DOI: 10.1016/j.brachy.2011.01.012
PubMed: 21397569
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000447
Links to Exploration step
pubmed:21397569Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Comparison of high-dose rate prostate brachytherapy dose distributions with iridium-192, ytterbium-169, and thulium-170 sources.</title><author><name sortKey="Krishnamurthy, Devan" sort="Krishnamurthy, Devan" uniqKey="Krishnamurthy D" first="Devan" last="Krishnamurthy">Devan Krishnamurthy</name><affiliation wicri:level="1"><nlm:affiliation>Department of Radiation Oncology, University of California San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94143-1708, USA. KrishnamurthyD@radonc.ucsf.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Radiation Oncology, University of California San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94143-1708</wicri:regionArea></affiliation></author><author><name sortKey="Weinberg, Vivian" sort="Weinberg, Vivian" uniqKey="Weinberg V" first="Vivian" last="Weinberg">Vivian Weinberg</name></author><author><name sortKey="Cunha, J Adam M" sort="Cunha, J Adam M" uniqKey="Cunha J" first="J Adam M" last="Cunha">J Adam M. Cunha</name></author><author><name sortKey="Hsu, I Chow" sort="Hsu, I Chow" uniqKey="Hsu I" first="I-Chow" last="Hsu">I-Chow Hsu</name></author><author><name sortKey="Pouliot, Jean" sort="Pouliot, Jean" uniqKey="Pouliot J" first="Jean" last="Pouliot">Jean Pouliot</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="????"><PubDate><MedlineDate>2011 Nov-Dec</MedlineDate></PubDate></date><idno type="doi">10.1016/j.brachy.2011.01.012</idno><idno type="RBID">pubmed:21397569</idno><idno type="pmid">21397569</idno><idno type="wicri:Area/PubMed/Corpus">000447</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000447</idno><idno type="wicri:Area/PubMed/Curation">000447</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000447</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Comparison of high-dose rate prostate brachytherapy dose distributions with iridium-192, ytterbium-169, and thulium-170 sources.</title><author><name sortKey="Krishnamurthy, Devan" sort="Krishnamurthy, Devan" uniqKey="Krishnamurthy D" first="Devan" last="Krishnamurthy">Devan Krishnamurthy</name><affiliation wicri:level="1"><nlm:affiliation>Department of Radiation Oncology, University of California San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94143-1708, USA. KrishnamurthyD@radonc.ucsf.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Radiation Oncology, University of California San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94143-1708</wicri:regionArea></affiliation></author><author><name sortKey="Weinberg, Vivian" sort="Weinberg, Vivian" uniqKey="Weinberg V" first="Vivian" last="Weinberg">Vivian Weinberg</name></author><author><name sortKey="Cunha, J Adam M" sort="Cunha, J Adam M" uniqKey="Cunha J" first="J Adam M" last="Cunha">J Adam M. Cunha</name></author><author><name sortKey="Hsu, I Chow" sort="Hsu, I Chow" uniqKey="Hsu I" first="I-Chow" last="Hsu">I-Chow Hsu</name></author><author><name sortKey="Pouliot, Jean" sort="Pouliot, Jean" uniqKey="Pouliot J" first="Jean" last="Pouliot">Jean Pouliot</name></author></analytic><series><title level="j">Brachytherapy</title><idno type="eISSN">1873-1449</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenocarcinoma (radiotherapy)</term><term>Brachytherapy (methods)</term><term>Humans</term><term>Iridium Radioisotopes (therapeutic use)</term><term>Male</term><term>Prostatic Neoplasms (radiotherapy)</term><term>Radioisotopes</term><term>Radiometry</term><term>Radiotherapy Dosage</term><term>Radiotherapy Planning, Computer-Assisted (methods)</term><term>Thulium (therapeutic use)</term><term>Ytterbium (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adénocarcinome (radiothérapie)</term><term>Curiethérapie ()</term><term>Dosimétrie en radiothérapie</term><term>Humains</term><term>Mâle</term><term>Planification de radiothérapie assistée par ordinateur ()</term><term>Radio-isotopes</term><term>Radio-isotopes de l'iridium (usage thérapeutique)</term><term>Radiométrie</term><term>Thulium (usage thérapeutique)</term><term>Tumeurs de la prostate (radiothérapie)</term><term>Ytterbium (usage thérapeutique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Iridium Radioisotopes</term><term>Thulium</term><term>Ytterbium</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Brachytherapy</term><term>Radiotherapy Planning, Computer-Assisted</term></keywords><keywords scheme="MESH" qualifier="radiotherapy" xml:lang="en"><term>Adenocarcinoma</term><term>Prostatic Neoplasms</term></keywords><keywords scheme="MESH" qualifier="radiothérapie" xml:lang="fr"><term>Adénocarcinome</term><term>Tumeurs de la prostate</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Radio-isotopes de l'iridium</term><term>Thulium</term><term>Ytterbium</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Male</term><term>Radioisotopes</term><term>Radiometry</term><term>Radiotherapy Dosage</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Curiethérapie</term><term>Dosimétrie en radiothérapie</term><term>Humains</term><term>Mâle</term><term>Planification de radiothérapie assistée par ordinateur</term><term>Radio-isotopes</term><term>Radiométrie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Recent studies have identified that among different available radionuclides, the dose characteristics and shielding properties of ytterbium-169 ((169)Yb) and thulium-170 ((170)Tm) may suit high-dose rate (HDR) brachytherapy needs. The purpose of this work was to compare clinically optimized dose distributions using proposed (169)Yb and (170)Tm HDR sources with the clinical dose distribution from a standard microSelectron V2 HDR iridium-192 ((192)Ir) brachytherapy source (Nucletron B.V., Veenendaal, The Netherlands).</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">21397569</PMID><DateCreated><Year>2011</Year><Month>11</Month><Day>04</Day></DateCreated><DateCompleted><Year>2012</Year><Month>02</Month><Day>21</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-1449</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>6</Issue><PubDate><MedlineDate>2011 Nov-Dec</MedlineDate></PubDate></JournalIssue><Title>Brachytherapy</Title><ISOAbbreviation>Brachytherapy</ISOAbbreviation></Journal><ArticleTitle>Comparison of high-dose rate prostate brachytherapy dose distributions with iridium-192, ytterbium-169, and thulium-170 sources.</ArticleTitle><Pagination><MedlinePgn>461-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.brachy.2011.01.012</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Recent studies have identified that among different available radionuclides, the dose characteristics and shielding properties of ytterbium-169 ((169)Yb) and thulium-170 ((170)Tm) may suit high-dose rate (HDR) brachytherapy needs. The purpose of this work was to compare clinically optimized dose distributions using proposed (169)Yb and (170)Tm HDR sources with the clinical dose distribution from a standard microSelectron V2 HDR iridium-192 ((192)Ir) brachytherapy source (Nucletron B.V., Veenendaal, The Netherlands).</AbstractText><AbstractText Label="METHODS AND MATERIALS" NlmCategory="METHODS">CT-based treatment plans of 10 patients having prostate volumes ranging from 17 to 92cm(3) were studied retrospectively. Clinical treatment of these patients involved 16 catheters and a microSelectron V2 HDR (192)Ir source. All dose plans were generated with inverse planning simulated annealing optimization algorithm. Dose objectives used for the (192)Ir radionuclide source were used for the other two radionuclides. The dose objective parameters were adjusted to obtain the same clinical target (prostate) volume coverage as the original (192)Ir radionuclide plan. A complete set of dosimetric indices was used to compare the plans from different radionuclides. A pairwise statistical analysis was also performed.</AbstractText><AbstractText Label="RESULTS AND CONCLUSIONS" NlmCategory="CONCLUSIONS">All the dose distributions optimized with specific (192)Ir, (169)Yb, and (170)Tm sources satisfied the standard clinical criteria for HDR prostate implants, such as those for the Radiation Therapy Oncology Group clinical trial 0321, for combined HDR and external beam treatment for prostate adenocarcinoma. For equivalent clinical target volume dose coverage, the specific (169)Yb and (170)Tm sources resulted in a statistically significant dose reduction to organs at risk compared with microSelectron V2 HDR (192)Ir source. This study indicates that a (170)Tm or (169)Yb radionuclide source may be an alternative to the (192)Ir radionuclide sources in HDR brachytherapy.</AbstractText><CopyrightInformation>Copyright © 2011 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Krishnamurthy</LastName><ForeName>Devan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, University of California San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94143-1708, USA. KrishnamurthyD@radonc.ucsf.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weinberg</LastName><ForeName>Vivian</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Cunha</LastName><ForeName>J Adam M</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>I-Chow</ForeName><Initials>IC</Initials></Author><Author ValidYN="Y"><LastName>Pouliot</LastName><ForeName>Jean</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>03</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Brachytherapy</MedlineTA><NlmUniqueID>101137600</NlmUniqueID><ISSNLinking>1538-4721</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007496">Iridium Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011868">Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>8RKC5ATI4P</RegistryNumber><NameOfSubstance UI="D013932">Thulium</NameOfSubstance></Chemical><Chemical><RegistryNumber>MNQ4O4WSI1</RegistryNumber><NameOfSubstance UI="D015018">Ytterbium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000230">Adenocarcinoma</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000532">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001918">Brachytherapy</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007496">Iridium Radioisotopes</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011471">Prostatic Neoplasms</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000532">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011868">Radioisotopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011874">Radiometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011879">Radiotherapy Dosage</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011880">Radiotherapy Planning, Computer-Assisted</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013932">Thulium</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015018">Ytterbium</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>5</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>1</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="aheadofprint"><Year>2011</Year><Month>3</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pii">S1538-4721(11)00023-7</ArticleId><ArticleId IdType="doi">10.1016/j.brachy.2011.01.012</ArticleId><ArticleId IdType="pubmed">21397569</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Terre/explor/ThuliumV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000447 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000447 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Terre
|area= ThuliumV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:21397569
|texte= Comparison of high-dose rate prostate brachytherapy dose distributions with iridium-192, ytterbium-169, and thulium-170 sources.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:21397569" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ThuliumV1
| This area was generated with Dilib version V0.6.21. |  |